In Phase 3 Huntington's Trial, Valbenazine Found to Ease Patients' Chorea
Treatment with valbenazine significantly lessened chorea motor symptoms in Huntington’s patients; an FDA submission is planned for 2022.| Huntington's Disease News
Treatment with valbenazine significantly lessened chorea motor symptoms in Huntington’s patients; an FDA submission is planned for 2022.| Huntington's Disease News
The online resource More Than HD is designed to help Huntington's patients and caregivers navigate their journey after a diagnosis.| Huntington's Disease News
